← All trials
NCT04594668
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 24, 2020
- Primary completion
- Apr 24, 2021
- Completion date
- Dec 31, 2021
- First posted
- Oct 20, 2020
- Last posted
- Oct 20, 2020
- Enrollment
- 46
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Aarhus UniversityLead sponsor
- Aarhus UniversityCollaborator
- Aarhus UniversityStudy chair
- Aarhus UniversityOverall official - principal investigator
- University of Southern DenmarkCollaborator
- University of Southern DenmarkOverall official - principal investigator
- University of CopenhagenCollaborator
- University of CopenhagenOverall official - principal investigator
- Aalborg UniversityCollaborator
- Aalborg UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.